Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020198613 - INHIBITION OF MONOAMINE OXIDASE SUBTYPE A (MAOA) MITIGATES CARDIOVASCULAR CALCIFICATION

Publication Number WO/2020/198613
Publication Date 01.10.2020
International Application No. PCT/US2020/025295
International Filing Date 27.03.2020
IPC
A61P 9/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
A61P 9/10 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
10for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 43/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43Drugs for specific purposes, not provided for in groups A61P1/-A61P41/108
Applicants
  • THE BRIGHAM AND WOMEN'S HOSPITAL, INC. [US]/[US]
Inventors
  • DECANO, Julius
  • AIKAWA, Elena
  • AIKAWA, Masanori
  • IWAMOTO, Yukio Francisco
Agents
  • DEYOUNG, Janice Kugler
  • FASSE, J., Peter
Priority Data
62/824,38327.03.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) INHIBITION OF MONOAMINE OXIDASE SUBTYPE A (MAOA) MITIGATES CARDIOVASCULAR CALCIFICATION
(FR) INHIBITION DU SOUS-TYPE A DE MONOAMINE OXYDASE (MAOA) ATTÉNUANT LA CALCIFICATION CARDIOVASCULAIRE
Abstract
(EN)
Compositions and methods for use in the treatment of disorders associated with aortic valve calcification. In some embodiments, the disorder is calcific aortic stenosis (CAS). Generally, the methods include administering a therapeutically effective amount of an inhibitor of MAOA as described herein, to a subject who is in need of, or who has been determined to be in need of, such treatment.
(FR)
L'invention concerne des compositions et des méthodes destinées à être utilisées dans le traitement de troubles associés à la calcification de la valve aortique. Dans certains modes de réalisation, le trouble est une sténose aortique calcifiée (CAS). De manière générale, les méthodes comprennent l'administration d'une quantité thérapeutiquement efficace d'un inhibiteur de MAOA tel que décrit dans cette invention, à un sujet en ayant besoin ou ayant été identifié comme ayant besoin d'un tel traitement.
Latest bibliographic data on file with the International Bureau